Advertisement

Preventive and Therapeutic Effect of Ganoderma (Lingzhi) on Liver Injury

Chapter
First Online:
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1182)

Abstract

Ganoderma lucidum (G. lucidum, Lingzhi) has a wide range of hepatoprotective effects. Its bioactive substances include triterpenoids, polysaccharides, sterols, steroids, peptides, and other bioactive ingredients. Based on our research and other references, this chapter discusses the hepatoprotective effects of G. lucidum in different liver diseases, including hepatocellular carcinoma, nonalcoholic liver disease, alcoholic liver disease, hepatitis B, inflammation, fibrosis, and toxicant-induced liver injury. The liver protective mechanisms of G. lucidum vary from diseases to diseases. This chapter will summarize the hepatoprotective effects of G. lucidum on different liver injury and their clinical applications.

Keywords

Ganoderma Lingzhi Polysaccharides Triterpenes Liver injury 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgment

Research in the authors’ laboratory is supported by National Natural Science Foundation of China grants 81620108029, 81330074, 81261160507, 81974083, and 81170632, Beijing National Natural Science Foundation grant 7172113, and 111 project.

References

  1. 1.
    Peng XR, Liu JQ, Wang CF, Li XY, Shu Y, Zhou L, Qiu MH (2014) Hepatoprotective effects of triterpenoids from Ganoderma cochlear[J]. J Nat Prod 77(4):737–743PubMedCrossRefGoogle Scholar
  2. 2.
    Liangping Z, Yuan Y, Luqi H (2016) Textual research on clinical efficacy of Lingzhi (Ganoderma) in ancient and modern China[J]. Modern Chin Med 18(5):653–656Google Scholar
  3. 3.
    Department of Pharmacology, Beijing Medical College (1974) Pharmacology of Ganoderma lucidum[J]. J Beijing Med Coll 4:246–254Google Scholar
  4. 4.
    Zhao C, Fan J, Liu Y, Guo W, Cao H, Xiao J, Wang Y, Liu B (2019) Hepatoprotective activity of Ganoderma lucidum triterpenoids in alcohol-induced liver injury in mice, an iTRAQ-based proteomic analysis[J]. Food Chem 271:148–156PubMedCrossRefGoogle Scholar
  5. 5.
    Yu Y, Qian L, Du N, Liu Y, Zhao X, Zhang X (2017) Ganoderma lucidum polysaccharide enhances radiosensitivity of hepatocellular carcinoma cell line HepG2 through Akt signaling pathway[J]. Exp Ther Med 14(6):5903–5907Google Scholar
  6. 6.
    Liu X, Yuan JP, Chung CK, Chen XJ (2002) Antitumor activity of the sporoderm-broken germinating spores of Ganoderma lucidum[J]. Cancer Lett 182(2):155–161PubMedCrossRefGoogle Scholar
  7. 7.
    Cai Q, Li Y, Pei G (2017) Polysaccharides from Ganoderma lucidum attenuate microglia-mediated neuroinflammation and modulate microglial phagocytosis and behavioural response[J]. J Neuroinflammation 14(1):63Google Scholar
  8. 8.
    Shen J, Park HS, Xia YM, Kim GS, Cui SW (2014) The polysaccharides from fermented Ganoderma lucidum mycelia induced miRNAs regulation in suppressed HepG2 cells[J]. Carbohydr Polym 103:319–324CrossRefGoogle Scholar
  9. 9.
    Zhang J, Tang Q, Zhou C, Jia W, Da Silva L, Nguyen LD, Reutter W, Fan H (2010) GLIS, a bioactive proteoglycan fraction from Ganoderma lucidum, displays anti-tumour activity by increasing both humoral and cellular immune response[J]. Life Sci 87(19–22):628–637PubMedCrossRefGoogle Scholar
  10. 10.
    Weng CJ, Fang PS, Chen DH, Chen KD, Yen GC (2010) Anti-invasive effect of a rare mushroom, Ganoderma colossum, on human hepatoma cells[J]. J Agric Food Chem 58(13):7657–7663PubMedCrossRefGoogle Scholar
  11. 11.
    Weng CJ, Chau CF, Yen GC, Liao JW, Chen DH, Chen KD (2009) Inhibitory effects of Ganoderma lucidum on tumorigenesis and metastasis of human hepatoma cells in cells and animal models[J]. J Agric Food Chem 57(11):5049–5057PubMedCrossRefGoogle Scholar
  12. 12.
    Liu YW, Gao JL, Guan J, Qian ZM, Feng K, Li SP (2009) Evaluation of antiproliferative activities and action mechanisms of extracts from two species of Ganoderma on tumor cell lines[J]. J Agric Food Chem 57(8):3087–3093PubMedCrossRefGoogle Scholar
  13. 13.
    Kleiner DE, Stetler-Stevenson WG (1999) Matrix metalloproteinases and metastasis[J]. Cancer Chemother Pharmacol 43(Suppl):S42–S51PubMedCrossRefGoogle Scholar
  14. 14.
    Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications[J]. J Clin Oncol 18(5):1135–1149PubMedCrossRefGoogle Scholar
  15. 15.
    Chen Y, Zou J, Li S, Huang G, Zheng Z, Dong Y, Yang M, Luo Y (2018) The inhibiting effects of Ganoderma lucidum polysaccharides on proliferation and migration of HepG2 liver cancer cells[J]. Guangdong Med J 39(11):1625–1628Google Scholar
  16. 16.
    Liu YJ, Shen J, Xia YM, Zhang J, Park HS (2012) The polysaccharides from Ganoderma lucidum: are they always inhibitors on human hepatocarcinoma cells?[J]. Carbohydr Polym 90(3):1210–1215PubMedCrossRefGoogle Scholar
  17. 17.
    Li N, Hu YL, He CX, Hu CJ, Zhou J, Tang GP, Gao JQ (2010) Preparation, characterisation and anti-tumour activity of Ganoderma lucidum polysaccharide nanoparticles[J]. J Pharm Pharmacol 62(1):139–144Google Scholar
  18. 18.
    Li A, Shuai X, Jia Z, Li H, Liang X, Su D, Guo W (2015) Ganoderma lucidum polysaccharide extract inhibits hepatocellular carcinoma growth by downregulating regulatory T cells accumulation and function by inducing microRNA-125b[J]. J Transl Med 13:100Google Scholar
  19. 19.
    Lin SB, Li CH, Lee SS, Kan LS (2003) Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest[J]. Life Sci 72(21):2381–2390PubMedCrossRefGoogle Scholar
  20. 20.
    Yang HL (2005) Ganoderic acid produced from submerged culture of Ganoderma lucidum induces cell cycle arrest and cytotoxicity in human hepatoma cell line BEL7402[J]. Biotechnol Lett 27(12):835–838PubMedCrossRefGoogle Scholar
  21. 21.
    Lu H, Song J, Jia XB, Feng L (2012) Antihepatoma activity of the acid and neutral components from Ganoderma lucidum[J]. Phytother Res 26(9):1294–1300PubMedCrossRefGoogle Scholar
  22. 22.
    Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters[J]. Nat Rev Cancer 2(1):48–58PubMedCrossRefGoogle Scholar
  23. 23.
    Dean M, Hamon Y, Chimini G (2001) The human ATP-binding cassette (ABC) transporter superfamily[J]. J Lipid Res 42(7):1007–1017PubMedGoogle Scholar
  24. 24.
    Liu DL, Li YJ, Yang DH, Wang CR, Xu J, Yao N, Zhang XQ, Chen ZS, Ye WC, Zhang DM (2015) Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells[J]. Int J Oncol 46(5):2029–2038PubMedCrossRefGoogle Scholar
  25. 25.
    Li X, Wu Q, Bu M, Hu L, Du WW, Jiao C, Pan H, Sdiri M, Wu N, Xie Y, Yang BB (2016) Ergosterol peroxide activates Foxo3-mediated cell death signaling by inhibiting AKT and c-Myc in human hepatocellular carcinoma cells[J]. Oncotarget 7(23):33948–33959PubMedPubMedCentralGoogle Scholar
  26. 26.
    Byrne CD, Targher G (2015) NAFLD: a multisystem disease[J]. J Hepatol 62(1 Suppl):S47–S64PubMedCrossRefGoogle Scholar
  27. 27.
    Cobbina E, Akhlaghi F (2017) Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters[J]. Drug Metab Rev 49(2):197–211PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Romero-Gomez M, Zelber-Sagi S, Trenell M (2017) Treatment of NAFLD with diet, physical activity and exercise[J]. J Hepatol 67(4):829–846PubMedCrossRefGoogle Scholar
  29. 29.
    Seto SW, Lam TY, Tam HL, Au AL, Chan SW, Wu JH, Yu PH, Leung GP, Ngai SM, Yeung JH, Leung PS, Lee SM, Kwan YW (2009) Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice[J]. Phytomedicine 16(5):426–436PubMedCrossRefGoogle Scholar
  30. 30.
    Jung S, Son H, Hwang CE, Cho KM, Park SW, Kim HJ (2018) Ganoderma lucidum ameliorates non-alcoholic steatosis by upregulating energy metabolizing enzymes in the liver[J]. J Clin Med 7(6):152PubMedCentralCrossRefGoogle Scholar
  31. 31.
    Zhong D, Xie Z, Huang B, Zhu S, Wang G, Zhou H, Lin S, Lin Z, Yang B (2018) Ganoderma Lucidum polysaccharide peptide alleviates hepatosteatosis via modulating bile acid metabolism dependent on FXR-SHP/FGF[J]. Cell Physiol Biochem 49(3):1163–1179PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Osna NA, Donohue TM Jr, Kharbanda KK (2017) Alcoholic liver disease: pathogenesis and current management[J]. Alcohol Res 38(2):147–161PubMedPubMedCentralGoogle Scholar
  33. 33.
    Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H (2018) Alcoholic liver disease[J]. Nat Rev Dis Primers 4(1):16PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Chung DJ, Yang MY, Li YR, Chen WJ, Hung CY, Wang CJ (2017) Ganoderma lucidum repress injury of ethanol-induced steatohepatitis via anti-inflammation, anti-oxidation and reducing hepatic lipid in C57BL/6J mice[J]. J Funct Foods 33:314–322CrossRefGoogle Scholar
  35. 35.
    Jang SH, Cho SW, Yoon HM, Jang KJ, Song CH, Kim CH (2014) Hepatoprotective evaluation of Ganoderma lucidum Pharmacopuncture: in vivo studies of ethanol-induced acute liver injury[J]. J Pharmacopuncture 17(3):16–24PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Li YQ, Wang SF (2006) Anti-hepatitis B activities of ganoderic acid from Ganoderma lucidum[J]. Biotechnol Lett 28(11):837–841PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Wang GJ, Huang YJ, Chen DH, Lin YL (2009) Ganoderma lucidum extract attenuates the proliferation of hepatic stellate cells by blocking the PDGF receptor[J]. Phytother Res 23(6):833–839PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Wu YW, Fang HL, Lin WC (2010) Post-treatment of Ganoderma lucidum reduced liver fibrosis induced by thioacetamide in mice[J]. Phytother Res 24(4):494–499Google Scholar
  39. 39.
    Lin WC, Lin WL (2006) Ameliorative effect of Ganoderma lucidum on carbon tetrachloride-induced liver fibrosis in rats[J]. World J Gastroenterol 12(2):265–270Google Scholar
  40. 40.
    Kwon SC, Kim YB (2011) Antifibrotic activity a fermentation filtrate of Ganoderma lucidum[J]. Lab Anim Res 27(4):369–371PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Long Y, Dong X, Yuan Y, Huang J, Song J, Sun Y, Lu Z, Yang L, Yu W (2015) Metabolomics changes in a rat model of obstructive jaundice: mapping to metabolism of amino acids, carbohydrates and lipids as well as oxidative stress[J]. J Clin Biochem Nutr 57(1):50–59PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Aydin S, Aytac E, Uzun H, Altug T, Mansur B, Saygili S, Buyukpinarbasili N, Sariyar M (2010) Effects of Ganoderma lucidum on obstructive jaundice-induced oxidative stress[J]. Asian J Surg 33(4):173–180CrossRefGoogle Scholar
  43. 43.
    Sudheesh NP, Ajith TA, Mathew J, Nima N, Janardhanan KK (2012) Ganoderma lucidum protects liver mitochondrial oxidative stress and improves the activity of electron transport chain in carbon tetrachloride intoxicated rats[J]. Hepatol Res 42(2):181–191PubMedCrossRefGoogle Scholar
  44. 44.
    Yang XJ, Liu J, Ye LB, Yang F, Ye L, Gao JR, Wu ZH (2006) In vitro and in vivo protective effects of proteoglycan isolated from mycelia of Ganoderma lucidum on carbon tetrachloride-induced liver injury[J]. World J Gastroenterol 12(9):1379–1385PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Huang CY, Chiu NC, Chi H, Huang FY, Chang PH (2018) Clinical manifestations, management, and outcomes of osteitis/osteomyelitis caused by Mycobacterium bovis Bacillus Calmette-Guerin in children: comparison by site(s) of affected bones[J]. J PediatrGoogle Scholar
  46. 46.
    Carpenter E, Fray L, Gormley E (1998) Antigen-specific lymphocytes enhance nitric oxide production in Mycobacterium bovis BCG-infected bovine macrophages[J]. Immunol Cell Biol 76(4):363–368PubMedCrossRefGoogle Scholar
  47. 47.
    Bai XY, Jia XH, Cheng LZ, Gu YD (2001) Influence of IFN alpha-2b and BCG on the release of TNF and IL-1 by Kupffer cells in rats with hepatoma[J]. World J Gastroenterol 7(3):419–421PubMedCentralCrossRefPubMedGoogle Scholar
  48. 48.
    Zhang GL, Wang YH, Ni W, Teng HL, Lin ZB (2002) Hepatoprotective role of Ganoderma lucidum polysaccharide against BCG-induced immune liver injury in mice[J]. World J Gastroenterol 8(4):728–733Google Scholar
  49. 49.
    Zhang G, Lin Z (1998) Effects of cytokines on the endotoxin stimulated nitric oxide production in the rat primary cultured hepatocytes[J]. J Beijing Med Univ 30(2):180–182Google Scholar
  50. 50.
    Wang X, Zhao X, Li D, Lou YQ, Lin ZB, Zhang GL (2007) Effects of Ganoderma lucidum polysaccharide on CYP2E1, CYP1A2 and CYP3A activities in BCG-immune hepatic injury in rats[J]. Biol Pharm Bull 30(9):1702–1706CrossRefGoogle Scholar
  51. 51.
    Wu CC, Bao LJ, Guo Y, Li SM, Zeng EY (2015) Barbecue fumes: An overlooked source of health hazards in outdoor settings?[J]. Environ Sci Technol 49(17):10607–10615PubMedCrossRefGoogle Scholar
  52. 52.
    Takaishi M, Sawada M, Shimada A, Suzuki JS, Satoh M, Nagase H (2009) Protective role of metallothionein in benzo[a]pyrene-induced DNA damage[J]. J Toxicol Sci 34(5):449–458PubMedCrossRefGoogle Scholar
  53. 53.
    Khalil A, Villard PH, Dao MA, Burcelin R, Champion S, Fouchier F, Savouret JF, Barra Y, Seree E (2010) Polycyclic aromatic hydrocarbons potentiate high-fat diet effects on intestinal inflammation[J]. Toxicol Lett 196(3):161–167PubMedCrossRefGoogle Scholar
  54. 54.
    Park SY, Phark S, Lee M, Lim JY, Sul D (2010) Anti-oxidative and anti-inflammatory activities of placental extracts in benzo[a]pyrene-exposed rats[J]. Placenta 31(10):873–879PubMedCrossRefGoogle Scholar
  55. 55.
    Lakshmi B, Ajith TA, Jose N, Janardhanan KK (2006) Antimutagenic activity of methanolic extract of Ganoderma lucidum and its effect on hepatic damage caused by benzo[a]pyrene[J]. J Ethnopharmacol 107(2):297–303PubMedCrossRefGoogle Scholar
  56. 56.
    Ma JQ, Liu CM, Qin ZH, Jiang JH, Sun YZ (2011) Ganoderma applanatum terpenes protect mouse liver against benzo(alpha)pyren-induced oxidative stress and inflammation[J]. Environ Toxicol Pharmacol 31(3):460–468Google Scholar
  57. 57.
    Li Y, Mu M, Yuan L, Zeng B, Lin S (2018) Challenges in the early diagnosis of patients with acute liver failure induced by amatoxin poisoning: two case reports[J]. Medicine 97(27):e11288PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Rudd MD, Luse DS (1996) Amanitin greatly reduces the rate of transcription by RNA polymerase II ternary complexes but fails to inhibit some transcript cleavage modes[J]. J Biol Chem 271(35):21549–21558PubMedCrossRefGoogle Scholar
  59. 59.
    Karlson-Stiber C, Persson H (2003) Cytotoxic fungi--an overview[J]. Toxicon 42(4):339–349PubMedCrossRefGoogle Scholar
  60. 60.
    Xiao GL, Zhang CH, Liu FY, Chen ZH, Hu SY (2007) Clinical experience in treatment of Amanita mushroom poisoning with Glossy Ganoderma Decoction and routine Western medicines[J]. Chin J Integr Med 13(2):145–147Google Scholar
  61. 61.
    Wu X, Zeng J, Hu J, Liao Q, Zhou R, Zhang P, Chen Z (2013) Hepatoprotective effects of aqueous extract from Lingzhi or Reishi medicinal mushroom Ganoderma lucidum (higher basidiomycetes) on alpha-amanitin-induced liver injury in mice[J]. Int J Med Mushrooms 15(4):383–391PubMedCrossRefGoogle Scholar
  62. 62.
    Wu JG, Kan YJ, Wu YB, Yi J, Chen TQ, Wu JZ (2016) Hepatoprotective effect of Ganoderma triterpenoids against oxidative damage induced by tert-butyl hydroperoxide in human hepatic HepG2 cells[J]. Pharm Biol 54(5):919–929PubMedCrossRefGoogle Scholar
  63. 63.
    Ha Do T, Oh J, Khoi NM, Dao TT, Dung Le V, Do TN, Lee SM, Jang TS, Jeong GS, Na M (2013) In vitro and in vivo hepatoprotective effect of ganodermanontriol against t-BHP-induced oxidative stress[J]. J Ethnopharmacol 150(3):875–885PubMedCrossRefGoogle Scholar
  64. 64.
    Li B, Lee DS, Kang Y, Yao NQ, An RB, Kim YC (2013) Protective effect of ganodermanondiol isolated from the Lingzhi mushroom against tert-butyl hydroperoxide-induced hepatotoxicity through Nrf2-mediated antioxidant enzymes[J]. Food Chem Toxicol 53:317–324PubMedCrossRefGoogle Scholar
  65. 65.
    Decker K, Keppler D (1972) Galactosamine induced liver injury[J]. Prog Liver Dis 4:183–199PubMedGoogle Scholar
  66. 66.
    Quintero A, Pedraza CA, Siendones E, Kamal Elsaid AM, Colell A, Garcia-Ruiz C, Montero JL, De La Mata M, Fernandez-Checa JC, Mino G, Muntane J (2002) PGE1 protection against apoptosis induced by D-galactosamine is not related to the modulation of intracellular free radical production in primary culture of rat hepatocytes[J]. Free Radic Res 36(3):345–355PubMedCrossRefGoogle Scholar
  67. 67.
    Shi Y, Sun J, He H, Guo H, Zhang S (2008) Hepatoprotective effects of Ganoderma lucidum peptides against D-galactosamine-induced liver injury in mice[J]. J Ethnopharmacol 117(3):415–419PubMedCrossRefGoogle Scholar
  68. 68.
    Wang M-Y, Liu Q, Che Q-M, Lin Z-B (2002) Effects of total triterpenoids extract from Ganoderma lucidum (Curt.: Fr.) P. Karst. (Reishi Mushroom) on experimental liver injury models induced by carbon tetrachloride or D-galactosamine in mice[J]. Int J Med Mushrooms 4:337–342Google Scholar
  69. 69.
    Peng XR, Liu JQ, Han ZH, Yuan XX, Luo HR, Qiu MH (2013) Protective effects of triterpenoids from Ganoderma resinaceum on H(2)O(2)-induced toxicity in HepG2 cells[J]. Food Chem 141(2):920–926Google Scholar
  70. 70.
    Song Z, Mcclain CJ, Chen T (2004) S-Adenosylmethionine protects against acetaminophen-induced hepatotoxicity in mice[J]. Pharmacology 71(4):199–208PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Masubuchi Y, Suda C, Horie T (2005) Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice[J]. J Hepatol 42(1):110–116PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Hsu CC, Lin KY, Wang ZH, Lin WL, Yin MC (2008) Preventive effect of Ganoderma amboinense on acetaminophen-induced acute liver injury[J]. Phytomedicine 15(11):946–950PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Fan S, Huang X, Wang S, Li C, Zhang Z, Xie M, Nie S (2018) Combinatorial usage of fungal polysaccharides from Cordyceps sinensis and Ganoderma atrum ameliorate drug-induced liver injury in mice[J]. Food Chem Toxicol 119:66–72PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Satarug S, Garrett SH, Sens MA, Sens DA (2010) Cadmium, environmental exposure, and health outcomes[J]. Environ Health Perspect 118(2):182–190PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Klaassen CD, Liu J, Choudhuri S (1999) Metallothionein: an intracellular protein to protect against cadmium toxicity[J]. Annu Rev Pharmacol Toxicol 39:267–294PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Jin H, Jin F, Jin JX, Xu J, Tao TT, Liu J, Huang HJ (2013) Protective effects of Ganoderma lucidum spore on cadmium hepatotoxicity in mice[J]. Food Chem Toxicol 52:171–175PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Smina TP, Joseph J, Janardhanan KK (2016) Ganoderma lucidum total triterpenes prevent gamma-radiation induced oxidative stress in Swiss albino mice in vivo[J]. Redox Rep 21(6):254–261PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Pillai TG, Nair CKK, Janardhanan KK (2008) Polysaccharides isolated from Ganoderma lucidum occurring in Southern parts of India, protects radiation induced damages both in vitro and in vivo[J]. Environ Toxicol Pharmacol 26(1):80–85PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Pedersen BK, Saltin B (2010) Evidence for prescribing exercise as therapy in chronic disease[J]. Scand J Med Sci Sports 16(S1):3–63CrossRefGoogle Scholar
  80. 80.
    Davies KJ, Quintanilha AT, Brooks GA, Packer L (1982) Free radicals and tissue damage produced by exercise[J]. Biochem Biophys Res Commun 107(4):1198–1205PubMedCrossRefGoogle Scholar
  81. 81.
    Huang CC, Huang WC, Yang SC, Chan CC, Lin WT (2013) Ganoderma tsugae hepatoprotection against exhaustive exercise-induced liver injury in rats[J]. Molecules 18(2):1741–1754PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Farzaei MH, Rahimi R, Farzaei F, Abdollahi M (2011) Traditional medicinal herbs for the management of diabetes and its complications: an evidence-based review[J]. Int J Pharmacol 11(7):874–887Google Scholar
  83. 83.
    Birkenfeld AL, Shulman GI (2014) Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes[J]. Hepatology 59(2):713–723PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Xiao C, Wu Q, Zhang J, Xie Y, Cai W, Tan J (2017) Antidiabetic activity of Ganoderma lucidum polysaccharides F31 down-regulated hepatic glucose regulatory enzymes in diabetic mice[J]. J Ethnopharmacol 196:47–57PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Zhu K, Nie S, Li C, Lin S, Xing M, Li W, Gong D, Xie M (2013) A newly identified polysaccharide from Ganoderma atrum attenuates hyperglycemia and hyperlipidemia[J]. Int J Biol Macromol 57:142–150CrossRefGoogle Scholar
  86. 86.
    Zhu KX, Nie SP, Tan LH, Li C, Gong DM, Xie MY (2016) A polysaccharide from Ganoderma atrum improves liver function in type 2 diabetic rats via antioxidant action and short-chain fatty acids excretion[J]. J Agric Food Chem 64(9):1938–1944PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical SciencesPeking UniversityBeijingChina
  2. 2.Department of Pharmacology, School of Basic Medical SciencesPeking UniversityBeijingChina

Personalised recommendations

Cite chapter

Buy options